The Checkmate 040 randomized clinical trial investigated the effectiveness and safety of ipilimumab in combination with nivolumab, monoclonal antibodies that target CTLA-4 and PD-1 immune checkpoints, respectively, among advanced HCC patients who had previously received sorafenib treatment [104]. Here, PDCD1 is linked to hepatocellular carcinoma.